XOMA (NASDAQ:XOMA) Lowered to Sell Rating by StockNews.com

XOMA (NASDAQ:XOMA) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.

Separately, HC Wainwright dropped their target price on shares of XOMA from $123.00 to $104.00 and set a “buy” rating on the stock in a research report on Monday.

XOMA Stock Down 6.5 %

Shares of NASDAQ XOMA traded down $1.73 during mid-day trading on Monday, reaching $24.88. 48,158 shares of the company traded hands, compared to its average volume of 62,093. The company’s fifty day moving average is $27.72 and its two-hundred day moving average is $28.07. XOMA has a fifty-two week low of $19.50 and a fifty-two week high of $35.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The stock has a market cap of $293.09 million, a PE ratio of -7.15 and a beta of 0.90.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.05. The business had revenue of $7.20 million during the quarter, compared to the consensus estimate of $6.66 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. On average, analysts expect that XOMA will post -1.41 earnings per share for the current year.

Insider Buying and Selling at XOMA

In other news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the firm’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Owen Hughes sold 21,881 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total value of $655,335.95. Following the completion of the transaction, the chief executive officer now owns 34,979 shares in the company, valued at $1,047,621.05. The trade was a 38.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.20% of the company’s stock.

Hedge Funds Weigh In On XOMA

Large investors have recently made changes to their positions in the company. Ellsworth Advisors LLC bought a new stake in shares of XOMA in the 3rd quarter valued at about $516,000. Barclays PLC increased its stake in XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 8,447 shares in the last quarter. State Street Corp raised its holdings in XOMA by 1.2% in the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after purchasing an additional 1,754 shares during the period. Rhumbline Advisers boosted its position in shares of XOMA by 18.1% during the fourth quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 1,699 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of XOMA by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after buying an additional 1,138 shares during the period. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.